Cargando…

The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach

AIMS: Cathepsin D is a ubiquitous lysosomal protease that is primarily secreted due to oxidative stress. The role of circulating cathepsin D in heart failure (HF) is unknown. The aim of this study is to determine the association between circulating cathepsin D levels and clinical outcomes in patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoes, Martijn F., Tromp, Jasper, Ouwerkerk, Wouter, Bomer, Nils, Oberdorf‐Maass, Silke U., Samani, Nilesh J., Ng, Leong L., Lang, Chim C., van der Harst, Pim, Hillege, Hans, Anker, Stefan D., Metra, Marco, van Veldhuisen, Dirk J., Voors, Adriaan A., van der Meer, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2019
Materias:	Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754332/ https://www.ncbi.nlm.nih.gov/pubmed/31797504 http://dx.doi.org/10.1002/ejhf.1674

Ejemplares similares

Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin–angiotensin–aldosterone system in patients with heart failure
por: Boorsma, Eva M., et al.
Publicado: (2021)

Selenium and outcome in heart failure
por: Bomer, Nils, et al.
Publicado: (2019)

Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF
por: Markousis-Mavrogenis, George, et al.
Publicado: (2021)

Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction
por: Woolley, Rebecca J., et al.
Publicado: (2021)

Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation
por: Mordi, Ify R., et al.
Publicado: (2019)

A Clinical Tool to Predict Low Serum Selenium in Patients with Worsening Heart Failure
por: Al-Mubarak, Ali A., et al.
Publicado: (2020)

Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment
por: Nauta, Jan F., et al.
Publicado: (2019)

Clinical implications of low estimated protein intake in patients with heart failure
por: Streng, Koen W., et al.
Publicado: (2022)

A network analysis to identify pathophysiological pathways distinguishing ischaemic from non‐ischaemic heart failure
por: Sama, Iziah E., et al.
Publicado: (2020)

Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2022)

Renal dysfunction is associated with shorter telomere length in heart failure
por: Wong, Liza S. M., et al.
Publicado: (2009)

The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure
por: Santema, Bernadet T., et al.
Publicado: (2019)

Correction to: The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure
por: Santema, Bernadet T., et al.
Publicado: (2020)

A combined bioinformatics, experimental and clinical approach to identify novel cardiac‐specific heart failure biomarkers: is Dickkopf‐3 (DKK3) a possible candidate?
por: Piek, Arnold, et al.
Publicado: (2020)

Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure
por: Markousis-Mavrogenis, George, et al.
Publicado: (2023)

Statins in the Treatment of Chronic Heart Failure: A Systematic Review
por: van der Harst, Pim, et al.
Publicado: (2006)

Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use
por: van der Wal, Haye H, et al.
Publicado: (2019)

Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction
por: ter Maaten, Jozine M., et al.
Publicado: (2020)

Systemic oxidative stress associates with disease severity and outcome in patients with new-onset or worsening heart failure
por: de Koning, Marie-Sophie L. Y., et al.
Publicado: (2023)

Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure
por: Ceelen, Daan, et al.
Publicado: (2022)

Genetic risk and atrial fibrillation in patients with heart failure
por: Kloosterman, Mariëlle, et al.
Publicado: (2020)

Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction
por: Tromp, Jasper, et al.
Publicado: (2017)

Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: The NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial
por: Maisel, Alan S., et al.
Publicado: (2011)

Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF
por: Pagnesi, Matteo, et al.
Publicado: (2021)

Sexual dimorphism in selenium deficiency is associated with metabolic syndrome and prevalence of heart disease
por: Weening, Eerde H., et al.
Publicado: (2023)

Concise Review: The Current State of Human In Vitro Cardiac Disease Modeling: A Focus on Gene Editing and Tissue Engineering
por: Hoes, Martijn F., et al.
Publicado: (2018)

Insulin‐like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence
por: Bracun, Valentina, et al.
Publicado: (2022)

Erythropoietin in the General Population: Reference Ranges and Clinical, Biochemical and Genetic Correlates
por: Grote Beverborg, Niels, et al.
Publicado: (2015)

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction
por: de Boer, Rudolf A, et al.
Publicado: (2011)

Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure
por: Kobayashi, Masatake, et al.
Publicado: (2021)

Additional burden of iron deficiency in heart failure patients beyond the cardio‐renal anaemia syndrome: findings from the BIOSTAT‐CHF study
por: Alnuwaysir, Ridha I.S., et al.
Publicado: (2021)

The value of spot urinary creatinine as a marker of muscle wasting in patients with new‐onset or worsening heart failure
por: Pandhi, Paloma, et al.
Publicado: (2021)

Neutrophil‐to‐lymphocyte ratio and outcomes in patients with new‐onset or worsening heart failure with reduced and preserved ejection fraction
por: Curran, Fraser M., et al.
Publicado: (2021)

Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure
por: Pagnesi, Matteo, et al.
Publicado: (2022)

Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure
por: Inciardi, Riccardo M., et al.
Publicado: (2022)

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency
por: van Veldhuisen, Dirk J., et al.
Publicado: (2017)

Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED‐HF study
por: Welsh, Paul, et al.
Publicado: (2017)

Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure
por: Kobayashi, Masatake, et al.
Publicado: (2020)

Current and novel renal biomarkers in heart failure
por: Damman, Kevin, et al.
Publicado: (2011)

Variability of biomarkers in patients with chronic heart failure and healthy controls
por: Meijers, Wouter C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_d4lg6rip72qo4g6fk86aitdku1